Large biomarker study underscores that ‘omega-6’ is not one uniform category—and highlights the value of measuring fatty acids in blood
February 26, 2026, Sioux Falls, SD: A major prospective study in the UK Biobank reports that higher plasma linoleic acid (LA)—the most common omega-6 fattyacid in the diet—was associated with a lower risk of incident dementia, while higher levels of non-LA omega-6 polyunsaturated fatty acids (n-6 PUFAs) were associated with a higher risk.
The findings, published online ahead of print in The American Journal of Clinical Nutrition, add important nuance to longstanding debate about omega-6 fats and brain health.
Key findings (at a glance)
- Population: 273,795 UK Biobank participants free of dementia at baseline
- Follow-up: Median 15.06 years
- Outcomes: 5,799 incident dementia cases identified during follow-up
- Linoleic acid (LA): Highest vs. lowest quintile associated with 18% lower dementia risk
- Non-LA n-6 PUFAs: Highest vs. lowest quintile associated with 21% higher dementia risk
“These results reinforce a critical point: we shouldn’t treat omega-6 fatty acids as a single, interchangeable group,” said William S. Harris, PhD, senior author and President of the Fatty Acid Research Institute (FARI). “In this analysis, the largest of its kind, linoleic acid tracked with lower dementia risk, while other omega-6 fats tracked with higher risk—an important distinction for researchers and clinicians.”
The authors used objective blood biomarkers (plasma fatty acids) and adjusted for multiple factors reported to relate to dementia risk. While the study is observational and cannot prove cause-and-effect, it provides strong evidence that different omega-6 fatty acids may have meaningfully different associations with long-term brain outcomes.
“Nutrition debates often get oversimplified,” added Aleix Sala-Vila, PhD, lead author of the study. “Our findings support the growing view that ‘omega-6’ is not one thing, and they motivate future work to test whether dietary patterns that raise plasma linoleic acid may help reduce dementia risk.”
But the “why” question remains: why would high levels of the major omega-6 (LA) be associated with lower dementia risk while high levels of other omega-6s be associated with higher risk? [This pattern was also seen in another UKBB study on total mortality (1)].
What exactly are “non-LA omega-6” fatty acids? LA constitutes 75% of the plasma omega-6 fatty acids, and 6 other omega-6s together make up the other 25%, and of this, arachidonic acid (AA, 20:4n6) is by far the major player at 77%.
The 5 other omega-6s (gamma-linolenic, dihomo-gamma-linolenic, eicosadienoic, adrenic and docosapentaenoic acids – 18:3n6, 20:3n6, 20:2n6, 22:4n6 and 22:5n6, respectively) make up only 5.8% of the plasma omega-6 fatty acids. So, the logical conclusion would be that “non-LA n6” would essentially be AA, but this needs further study since the analytical method used in the UKBB to measure non-LA n6 is not strongly correlated with plasma AA levels.
OmegaQuant and FARI work with researchers and clinicians worldwide to measure fatty acids and interpret biomarker data. Studies like this one demonstrate why blood measurements can be especially informative: they reflect not only intake, but also absorption, metabolism, and physiology—helping clarify relationships between fatty acids and health outcomes.
<END>
Study Link:
Reference:
- Harris WS, Westra J, Tintle NL, Sala-Vila A, Wu JHY, Marklund M. Plasma n6 polyunsaturated fatty acid levels and risk for total and cause-specific mortality: A prospective observational study from the UK Biobank. Am J Clin Nutr. 2024.
Media Inquiries:
Becky Wright
Marketing Communications Director, OmegaQuant
+1-201-675-0197
About OmegaQuant:
OmegaQuant is an independent, CLIA-certified lab that offers nutritional status testing to researchers, clinicians and the public. OmegaQuant performs analysis in Sioux Falls, SD, for commercial and academic research collaborators, and for consumers interested in monitoring their nutritional status in both blood and breast milk. Its goal is to offer the highest quality fatty acid analytical services to researchers and to provide simple tests of nutritional status to consumers, with the ultimate purpose of advancing the science and use of certain nutrients to improve health. Internationally, OmegaQuant works with the University of Stirling, based in the Scotland, to help process blood samples from Europe. Learn more @ www.omegaquant.com
About FARI:
FARI was established in 2020 as a non-profit foundation that brings together nutrition scientists and biostatistical experts with strong publication records and expertise in fatty acids to accelerate discovery of the relationship between fatty acids, especially omega-3s, and health. FARI is currently the only organization focused directly on discovering and publishing research evaluating the health effects of individual fatty acids. Learn more @ www.faresinst.org